In recent news, McKesson Corporation (MCK) has seen some significant developments and achieved notable milestones. The company has experienced strong trading days outperforming competitors and also had considerable investor attention. The divestiture of Canada-based Rexall and Well.ca allows McKesson to focus on growth in oncology and biopharma.
The company has been the talk amongst institutions with around 89% of the shares being held by institutional owners. Despite mixed views by analysts, the company has garnered positive encouragement from financial advisor Jim Cramer, stating 'it's time to buy it'.
Moreover, McKesson has also declared its quarterly dividend and made bold predictions for the future, including raising full-year EPS guidance following Q2 earnings beat. However, the company’s shares did decline following the divestiture news, and it faced a big revenue miss where EPS soared but revenue missed the mark. Even with these negative fluctuations, several analysts believe the stock is a top value for the long-term. Also, McKesson has continued to attract investor interest and is waiting for a pull back.
Mckesson Corporation MCK News Analytics from Tue, 07 May 2024 07:00:00 GMT to Fri, 10 Jan 2025 23:20:20 GMT - Rating 6 - Innovation 4 - Information 7 - Rumor -3
